EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:EPRX - CA29842P1053 - Common Stock
EPRX.CA Key Statistics, Chart & Performance
The current stock price of EPRX.CA is 10.02 CAD. In the past month the price increased by 14.91%. In the past year, price increased by 123.16%.
EPRX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 367.23M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 183.31M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 78.41M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.71 | 47.78M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 31.97M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 25.86M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 21.13M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.02M | ||
| MPH.CA | MEDICURE INC | N/A | 12.63M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.54M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 6.69M |
Related stock screener links
About EPRX.CA
Company Profile
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Company Info
EUPRAXIA PHARMACEUTICALS INC
201-2067 Cadboro Bay Rd.
Victoria BRITISH COLUMBIA CA
CEO: James A. Helliwell
Employees: 33
Phone: 12505903968
EUPRAXIA PHARMACEUTICALS INC / EPRX.CA FAQ
What does EPRX do?
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Can you provide the latest stock price for EUPRAXIA PHARMACEUTICALS INC?
The current stock price of EPRX.CA is 10.02 CAD. The price increased by 0.2% in the last trading session.
What is the dividend status of EUPRAXIA PHARMACEUTICALS INC?
EPRX.CA does not pay a dividend.
How is the ChartMill rating for EUPRAXIA PHARMACEUTICALS INC?
EPRX.CA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) stock traded?
EPRX.CA stock is listed on the Toronto Stock Exchange exchange.
What is EUPRAXIA PHARMACEUTICALS INC worth?
EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) has a market capitalization of 507.51M CAD. This makes EPRX.CA a Small Cap stock.
What is the ownership structure of EUPRAXIA PHARMACEUTICALS INC (EPRX.CA)?
You can find the ownership structure of EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) on the Ownership tab.
EPRX.CA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to EPRX.CA. When comparing the yearly performance of all stocks, EPRX.CA is one of the better performing stocks in the market, outperforming 86.33% of all stocks.
EPRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EPRX.CA. No worries on liquidiy or solvency for EPRX.CA as it has an excellent financial health rating, but there are worries on the profitability.
EPRX.CA Financial Highlights
Over the last trailing twelve months EPRX.CA reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS decreased by -6.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.81% | ||
| ROE | -32.63% | ||
| Debt/Equity | 0 |
EPRX.CA Forecast & Estimates
10 analysts have analysed EPRX.CA and the average price target is 12.36 CAD. This implies a price increase of 23.31% is expected in the next year compared to the current price of 10.02.